| Study Period | 2019 - 2032 |
| Market Size in 2024 | USD 6.9 Billion |
| Market Size in 2025 | USD 8.2 Billion |
| Market Size by 2032 | USD 28.6 Billion |
| Projected CAGR | 19.6% |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Market Structure | Fragmented |
|
Explore the market potential with our data-driven report
The genome editing market revenue was USD 6.9 billion in 2024, and it is expected to witness a CAGR of 19.6% from 2025 to 2032, reaching USD 28.6 billion in 2032. This will majorly be a result of the growing pace of technological advancements in the field of genomics, rising focus on the highly adaptable CRISPR technology, and increasing investments by government as well as private organizations in genomics R&D. Additionally, the surging prevalence of numerous genetic disorders is expected to propel the market.
In recent years, the development in the field of genomics has significantly improved the gene editing capabilities, thus enabling the alteration of the genetic sequences of interest in a number of cell types and model organisms. Furthermore, the use of genetic engineering is not limited to large research organizations, such as academic and government research centers, but it has now progressed as a potent diagnostic tool, especially for oncologic studies. This is leading to the rapid developments in DNA editing technologies, thus propelling the growth of the market.
Moreover, the presence of major players in the developing nations and widening application of genome editing in the process of drug discovery are creating lucrative growth opportunities for the market advance. Furthermore, researchers are using CRISPR gene editing technology to engineer a bacterium that can detect tumors in mice colons.
The escalating use of personalized medicine is offering immense growth opportunities to the players in the industry. With the use of personalized medicine, a medical practitioner is able to recognize the exact requirement of the patient and provide the specific treatment, accordingly. Hence, many pharma and biotech firms and medical academic institutions around the world are initiating research projects in order to develop precision medicines, for catering to the specific treatment requirements of patients.
With the technological advancement and progress in the genome editing, there arise challenges regarding the accuracy, efficiency, and delivery of gene editing tools. CRISPR-Cas9 is widely used in genome editing still faces issues in off-target effects. Another major challenge is the delivery of the gene-editing tools, which sometimes might not give the desired results, which can create unintended interactions. Furthermore, another challenge is in the targeting a broad range of cell types and tissues, further hampering the market growth.
Reagents & consumables emerged as the largest offering category in the market, with around 65% revenue share, in 2024, and they are also expected to retain their dominance during the forecast period. The growth in the demand for reagents and consumables can be primarily ascribed to their extensive usage in research projects and studies and their exhaustible nature, due to which there is a repetitive purchase.
The services category is the fastest-growing, with a CAGR of 19.9% during the forecast period. There is a rise in the demand for genetic engineering, consulting, custom gene synthesis, genome sequencing and CRISPR-mediated gene editing services from small biotech firms, which rely on service providers for contract research and clinical trials.
Based on offering, the market has the following categories:
The CRISPR technology held the major share of 65%, in 2024. Due to its ease of use, inexpensive nature compared to other technologies, and higher efficiency. The need for the technology is rising for the identification and treatment of several disorders, such as cancer, hepatitis B, and even high cholesterol, as they involve the genetic component. This technology has a potential to develop solutions for many more serious disorders, including Huntington's disease and human immunodeficiency virus (HIV). Studies have shown that Huntington's disease occurs due to a mutated gene, and through the usage of the CRISPR technology in a recent study, the production of the mutant gene was lowered by roughly 90% in mouse models.
Additionally, with the growing pace of advancements in the field, researchers can now discover the important genes in disease pathogenesis with the help of gene knockouts in a healthy cell line. Moreover, several market players, including Caribou Biosciences, Takara Bio, and Thermo Fisher Scientific, are putting an emphasis on research and development for bringing about further innovations in the area of genomics.
Based on technology, the market has the following categories:
Drug discovery & development will grow at the higher CAGR of 19.8%, during the forecast period. The pharmaceutical and biotechnology industries use gene-editing technologies to create model organisms for testing potential drugs and developing personalized medicine. As per the International Federation of Pharmaceutical Manufacturers and Associations, the 50 biggest pharma companies in the world spent a combined USD 167 billion on R&D in 2022.
Genetic engineering held the largest market share of 70%, in 2024 which is attributed to the use of gene technologies in agriculture, industrial biotechnology, and environmental science. In agriculture, genome editing is used to produce genetically modified crops, which can resist pests and diseases and possess an improved nutritional content. Furthermore, genetic engineering is gaining popularity in industrial biotechnology to produce bio-based chemicals, biofuels, and synthetic materials.
Based on application, the market has the following categories:
Biotechnology & pharmaceutical companies accounted for the largest revenue share, of around 55%, in 2024. This is on account of the increasing usage of gene editing technologies by the major pharma and biopharma firms in drug discovery & target detection. The application of genome editing by these companies is focused on creating novel therapeutics for several disorders. In addition to that, several biotechnology companies are using these techniques to develop GM seeds and transgenic animals.
In this regard, the rising research and development activities, often in collaboration and partnership among academic institutes and industry players, are propelling the growth of the market.
Contract research organizations will grow at the highest CAGR of 20.1%, during the forecast period. This can be attributed to the increasing demand for outsourced research and development, expansion of genome editing applications, increasing number of partnerships and collaborations, and growing count of gene therapy trials. As per industry estimates, the worldwide spending on CRO services will increase from USD 69.1 billion in 2024 to USD 142.56 billion in 2030.
Based on end user, the market has the following categories:
Drive strategic growth with comprehensive market analysis
North America was the largest market, with a share of around 50%, in 2024. This is attributed to the high healthcare expenditure, huge investment in interventional studies, the increasing number of chronic diseases coupled with a large number of patients suffering from these illnesses, and governments are increasingly spending in this field in the region.
Furthermore, the region has a high personal income, due to which the demand for technologically advanced products has increased, and people are able to spend extensively on healthcare services. Also, there is strong healthcare awareness among individuals and high spending for the development of new medicines. Thus, these factors fuel the regional market growth.
In addition, owing to the development of gene therapy, rising use of genetically modified crops, and easy availability of research funding, the continent will continue the contribute the most significantly to companies offering tools and services for gene editing. In addition, the U.S. dominates the industry in North America, primarily due to the rising government and private funding for genomics research.
Moreover, the increasing incidence of rare disorders in the U.S. and Canada is propelling the genome editing market in the North American region. The National Institutes of Health (NIH) say that approximately 25 to 30 million Americans are affected by more than 7,000 rare disorders. This means 1 in 10 Americans are suffering from rare disorders. Thus, the increasing need for developing effective drugs drives the adoption of novel DNA editing tools in these countries.
APAC will have the highest CAGR, of 20.2%, during the forecast period. The genome editing market in the Asia-Pacific (APAC) region is driven by increasing research activity, growing biotech investments, and supportive government policies. Countries like China, Japan, and South Korea are advancing rapidly in CRISPR and gene therapy research. Over 50 clinical trials involving CRISPR are active in the region, focusing on oncology, rare diseases, and agriculture.
Academic-industry collaborations are common, particularly in China’s biopharmaceutical sector. Regulatory frameworks vary, but several nations are updating guidelines to accommodate gene editing innovations. Demand for precision medicine and genetically modified crops is also contributing to the growth of genome editing technologies in APAC.
Furthermore, the surging number of research activities in the domain of genomics in India, Japan, and China and the soaring investments being made by public and private organizations for gene editing purposes are the main factors propelling the advance of the market in the Asia-Pacific region.
Based on geography, the market has the following categories:
The market is fragmented in nature with a wide range of companies, startups, and research institutions, which are working on a diverse range of technologies, such as CRISPR-Cas9, TALENs, Zinc Finger Nucleases (ZFNs), and prime and base editing. The larger companies are collaborating with smaller biotech companies and academic institutions to make their position stronger in the market.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages